Nvidia to unveil first Windows PCs powered by its chips next week - Axios
SAN FRANCISCO and VANCOUVER, British Columbia - Jade Biosciences, Inc. (NASDAQ:JBIO) will host a conference call and webcast on Monday, June 1, 2026, at 8:00 a.m. ET to discuss results from its ongoing Phase 1 healthy volunteer study of JADE101, according to a press release statement.The announcement comes as the company’s stock has surged nearly 194% over the past year, currently trading at $21.04 with a market capitalization of $1.04 billion. The stock has gained 62.6% over the past six months alone.
The clinical-stage biotechnology company stated the data are expected to define the dosing strategy and characterize JADE101’s clinical profile as an anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN).
JADE101 is a fully human monoclonal antibody that blocks APRIL and is engineered for half-life extension. Preclinical studies showed IgA suppression after a single dose in non-human primates, with a serum half-life of approximately 27 days. The antibody was designed to avoid formation of high molecular weight immune complexes and supports potential subcutaneous dosing.According to InvestingPro analysis, Jade holds more cash than debt on its balance sheet and maintains liquid assets that exceed short-term obligations. However, the platform’s Fair Value analysis suggests the stock may be overvalued at current levels. Investors can access 6 additional InvestingPro Tips for deeper insights into the company’s financial health.
IgAN is a chronic autoimmune kidney disease affecting approximately 169,000 people in the United States and is most often diagnosed in young adults. The disease is characterized by deposition of pathogenic IgA-containing immune complexes in the kidneys, which can lead to proteinuria, declining kidney function, and potentially end-stage kidney disease requiring dialysis or transplant.
Investors and the public can access the live webcast through the Events and Presentations page of the company’s website. A replay will be available on the website after the call concludes.
Jade Biosciences’ pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an undisclosed antibody program. The company was launched based on assets licensed from Paragon Therapeutics.Wall Street analysts maintain a bullish outlook, with price targets ranging from $24 to $45. The next earnings report is scheduled for August 6, 2026.
In other recent news, Jade Biosciences has dosed the first participant in a Phase 1 clinical trial for JADE201, an investigational monoclonal antibody aimed at treating autoimmune diseases. Additionally, the company has initiated dosing in the JUNIPER Phase 2 trial for JADE101, targeting immunoglobulin A nephropathy (IgAN). H.C. Wainwright has raised its price target for Jade Biosciences from $35 to $45, maintaining a Buy rating, and increased the probability of launch for JADE101 in IgAN to 40%. In corporate developments, Jade Biosciences appointed Andrew King as President of Research and Development, a role he assumes after serving as Chief Scientific Officer. Furthermore, Edward R. Conner has been named Chief Medical Officer, where he will oversee the clinical and medical strategy for the company’s therapies. These appointments are part of the company’s broader strategy to enhance its leadership in the development of treatments for autoimmune diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.